Across borders | Know what travels and what must be rebuilt

The buyer could be a multi-country medicines business, an academic partner or an investor examining whether a workflow can scale. The first task would be to identify the same type of decision in two settings. Similar job titles are not sufficient: a payer, a hospital committee and a community pharmacy owner may control different parts of the process. We would compare authority, inputs and incentives before discussing a shared commercial proposition.

We propose taking one non-patient-specific evidence-preparation question in two authorised settings. Each partner would provide its own brief, approved source set and local implementation criteria. The study would compare usual preparation with a common structured approach adapted transparently to each setting. The objective would be to discover which parts remain useful and which require redesign, before attempting any integration or live operational change.

The study would retain population definitions, product mappings, data periods and measurement units. Public aggregate datasets would not be assumed to describe identical activity. A prescription, an item, a pack and a patient are different denominators. We would document exclusions and revisions, and avoid country rankings where the source coverage is incompatible. A shared visual language should make those differences easier to read, not conceal them behind matching chart shapes.

We would stop a cross-border comparison if the decision remits differ too much, data cannot be reconciled or no local reviewer can validate the interpretation. The study would not pool results simply to make a sample look larger. Any later transfer would need a new local feasibility and governance check. A useful prototype, an enthusiastic meeting or an internationally accessible website would not establish regulatory permission, an operating presence or a customer in that market.

An investable international proposition would show a repeated buyer problem, a maintainable method and a realistic cost of local adaptation. The next commercial step could be a bounded evaluation in the second setting, with clear deliverables and review ownership. We would keep market interest separate from contracted work and proven value. International ambition becomes more credible when it identifies what must be learned next and what evidence would justify committing resources.

Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.